Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07174583 · ClinicalTrials.gov registry record · Phase 1

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

A Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinomas, sponsored by IDEAYA Biosciences.

Recruiting
Registry status
Phase 1
Development phase
208
Enrollment target
20
Study locations

NCT07174583 is a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinomas that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 208 participants, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07174583, a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinomas, is actively recruiting participants, sponsored by IDEAYA Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
208 participants
Enrollment target
20
Study locations

Study Summary

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Conditions Studied

Small-cell Lung Cancer Neuroendocrine Carcinomas Solid Tumor Show to Express DLL3

Interventions

  • DRUG IDE849
  • DRUG durvalumab
  • DRUG IDE161

Study Locations (20)

Texas

  • The University of Texas MD Anderson Cancer Center Houston, Texas 77030-4000 - Houston
  • Oncology Consultants, PA - Houston - Houston
  • Next Oncology Dallas - Irving

Florida

  • Mayo Clinic Hospital - Florida - Jacksonville
  • Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando

Illinois

  • The University of Chicago Medical Center - Duchossois Center for Advanced Medicine - Chicago
  • OSF HealthCare Cancer Institute - Peoria

Michigan

  • Trinity Health-IHA Medical Group - Hematology Oncology - Ann Arbor Campus - Ann Arbor
  • The Cancer and Hematology Centers - Grand Rapids

New York

  • Columbia University Medical Center - Herbert Irving Pavilion - New York
  • Weill Cornell Medicine - Cutaneous Oncology and Melanoma Program - New York

Washington

  • Swedish Cancer Institute - Seattle
  • Seattle Cancer Care Alliance - Seattle

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Georgia

  • Piedmont Physicians Medical Oncology - Atlanta - Atlanta

Trial Details

FieldValue
Enrollment Target 208 participants
Start Date 2025-10-14
Est. Completion 2029-05
Phase Phase 1

Sponsor

IDEAYA Biosciences

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07174583

The ClinicalTrials.gov registry entry for NCT07174583 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (10% lower). The listed sponsor is IDEAYA Biosciences, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which IDE849 is the first listed.

NCT07174583 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT07174583 about?

NCT07174583 is a clinical study titled "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer". This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

What is the current status of trial NCT07174583?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 208 participants. The study started on 2025-10-14. Estimated completion is 2029-05.

What conditions does trial NCT07174583 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3.

What interventions are being tested in trial NCT07174583?

The interventions under investigation include: IDE849 (DRUG), durvalumab (DRUG), IDE161 (DRUG).

Who is sponsoring clinical trial NCT07174583?

This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07174583 being conducted?

This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

Neuroendocrine Carcinomas

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.